Wize Pharma has entered into an exclusive license agreement to develop and commercialize products based on non-viral gene therapy technology from Copernicus Therapeutics, the company announced in a press release.
WP-REP1, Wize’s gene therapy product based on Copernicus’ technology, will be comprised of DNA compromised nanoparticles and designed to treat choroideremia. It will be administered via intraocular injection and provide a functioning CHM gene to photoreceptors and retinal pigment epithelial cells.
“We are very pleased and excited to enter into this agreement with Copernicus. Their proprietary and innovative technology addresses what we believe to be the greatest challenges in gene therapy, including overcoming the potential immune system response to treatment, thereby allowing repeated treatments if necessary. As an ophthalmology-focused company, Wize is eager to develop and commercialize this cutting-edge gene therapy to transform the treatment of eye-related diseases,” Mark Sieczkarek, chairman of the board of directors of Wize, said in the release.
Under the terms of the license agreement, Wize will receive a worldwide exclusive license to develop, manufacture and commercialize the technology and patents for the treatment of choroideremia. Wize will pay a one-time license fee and royalty payments depending on net sales thresholds reached.